Literature DB >> 8525532

Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts.

P A Andrews1, J E Finn, P W Mathieson, S H Sacks.   

Abstract

The third component of complement (C3) exists in two main allotypic forms, C3S and C3F, which can be distinguished at the molecular level using a variation of the polymerase chain reaction. An increased frequency of the C3F allele has been noted in a number of autoimmune and inflammatory conditions affecting the kidney, including systemic vasculitis, IgA nephropathy, and type II mesangiocapillary nephritis. Recently, in an unrelated study, we found (with small numbers) an increased incidence of graft loss associated with the presence of the C3F allele. To further assess this, we analyzed the S/F polymorphism in 183 donor-recipient pairs of patients undergoing renal transplantation. Forty-one of 183 grafts were lost, but graft loss was not associated with the C3F allele over 14-month follow-up. However, the presence of the C3F allele predicted an increased risk of graft dysfunction (defined as serum creatinine > 150 mumol/L): 61/105 versus 36/78, with a relative risk of 1.4 (P < 0.05). The C3F allele predisposed toward graft dysfunction when present in either donor or recipient. The presence of two C3F alleles gave a relative risk for graft dysfunction of 1.8, suggesting a dose-dependent effect, although numbers were small. The presence of the C3F allele was not significantly correlated with the number of rejection episodes, serum creatinine, or duration of primary nonfunction. These findings suggest that C3F may be a susceptibility allele for allograft injury. Possible mechanisms for this association are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525532

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  In situ localization of C3 synthesis in experimental acute renal allograft rejection.

Authors:  J R Pratt; K Abe; M Miyazaki; W Zhou; S H Sacks
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

Review 2.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

3.  C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.

Authors:  Mohamed Jalloul Nsaiba; Marc Lapointe; Hajer Mabrouk; Wahiba Douki; Lotfi Gaha; Louis Pérusse; Claude Bouchard; Besma Bel Hadj Jrad; Katherine Cianflone
Journal:  Neurochem Res       Date:  2015-02-27       Impact factor: 3.996

4.  Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.

Authors:  Meike Heurich; Ruben Martínez-Barricarte; Nigel J Francis; Dawn L Roberts; Santiago Rodríguez de Córdoba; B Paul Morgan; Claire L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

Review 5.  The complotype: dictating risk for inflammation and infection.

Authors:  Claire L Harris; Meike Heurich; Santiago Rodriguez de Cordoba; B Paul Morgan
Journal:  Trends Immunol       Date:  2012-06-29       Impact factor: 16.687

6.  The immunomodulatory role of carbon monoxide during transplantation.

Authors:  Mariane Tami Amano; Niels Olsen Saraiva Camara
Journal:  Med Gas Res       Date:  2013-01-07

7.  A Single Nucleotide C3 Polymorphism Associates With Clinical Outcome After Lung Transplantation.

Authors:  Tineke Kardol-Hoefnagel; Kevin Budding; Eduard A van de Graaf; Jessica van Setten; Oliver A van Rossum; Erik-Jan D Oudijk; Henderikus G Otten
Journal:  Front Immunol       Date:  2019-09-26       Impact factor: 7.561

Review 8.  Membrane attack complexes, endothelial cell activation, and direct allorecognition.

Authors:  Guiyu Song; Shaoxun Wang; Mahsa Nouri Barkestani; Clancy Mullan; Matthew Fan; Bo Jiang; Quan Jiang; Xue Li; Dan Jane-Wit
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.